I'm very proud to announce the recent publication of this paper on @ARVOtvst: https://t.co/YEVKLf7kdb This is both the first publication out of my PhD and a breakthrough in #RPD research. @Moorfields @MoorfieldsBRC @cdt_ai_health

🔬 Exciting findings from #EURETINA24! Dr. Roy Schwartz unveiled unique genetic determinants of Reticular Pseudodrusen in a groundbreaking study. Understanding these pathways could be key to future AMD treatments. 🔗 Read More: https://t.co/DBFLyVVwsq #RetinaCare

I was privileged to be invited to talk at the #Floretina/#ICOOR meeting in Rome today, presenting the challenge in identifying different stages of #RPD for #AI and for humans. @Moorfields @MoorfieldsBRC @cdt_ai_health @RetinaDiscovery

Thanks to everyone involved, including @adnan_tufail1, Clarisa Sánchez, @h_a_khalid, Sandra Liakopoulos, Yanling Ouyang, Coen de Vente, Cristina González, @aaronylee, Robyn Guymer, Emily Chew, @joe_farrington, @PhilippLMuller and others!

This #AI framework detects different stages of #RPD as well as drusen and will serve as an invaluable research tool for further discoveries! 🔬

#RPD are risk factors for advanced #AMD, leading to vision loss in many patients. There is still we don't understand about this phenotype.

Roy Schwartz @royschwartz et al. develop and validate a deep learning framework for the detection and quantification of reticular pseudodrusen (RPD) and drusen on optical coherence tomography (OCT) scans. @UCL @Moorfields @NatEyeInstitute @aaronylee https://t.co/YRsw7Rbcwm

Out now! An important paper raising the issue of under-registration of visual impairment in England for patients with diabetic retinopathy. Even with busy clinics, we need to consider patients with DR as visually impaired, as many of them are.

I'm excited to share that I've joined @ApellisPharma as Medical Advisor, Ophthalmology. It's a historical time for patients with #GA and I'm extremely proud to take part in it!

I was honoured to (virtually) speak this morning at the #EURETINA2022 conference about the results of our study on reticular pseudodrusen and plans for the future. Thank you @EURETINA for supporting this important endeavour!

An important study from our group, shedding light on macular curvature and an important step in macular and myopia research. Out now!

How common is common? New insights into Macular Curvature and Dome-Shaped Configuration based on data from the unique UK Biobank. This may open new fields to future #myopia and #macula research! @RetinaDiscovery

We also illustrate real-world examples of the pandemic's effect on retina services in 15 countries across four continents 🌎. 🧵(3/3)

In this review from our group (the International Retina Collaborative), led by the brilliant Anna Tan, we aimed to provide evidence-based guidelines on managing IVT during a pandemic in common macular diseases. 🧵(2/3) https://t.co/wWhsjCm50b

Just published 📣: #COVID-19 significantly affected the daily functioning of hospitals in general and retina clinics in particular, affecting our ability to deliver intravitreal treatment (IVT) to our patients.🧵(1/3)

A useful summary for retina clinicians to help them make the right choices for their patients when using OCTA

It includes information about the diagnostic accuracy of OCTA in #nAMD, its use as a tool to confirm the diagnosis, patient follow-up, and diagnosis of the elusive non-exudative MNV.

In this editorial, we provide a useful summary for retina clinicians to help them make the right choices for their patients when using this imaging modality, given the current literature 📖.

Our new editorial was just published! 📣 OCTA has become an invaluable tool in our daily clinics as retina specialists. It shines the most in the diagnosis of macular neovascularisation (MNV) associated with #AMD. https://t.co/qHR6YSbMwH

I had the pleasure to present our study at #ARVO2022 today. Our deep learning framework is another step in unlocking the mystery of #RPD! 🔑@RetinaDiscovery